SD Biosensor and SJL Partners Acquire Meridian Bioscience for $1.53B
July 7, 2022
A consortium led by SD Biosensor and private equity firm SJL Partners agreed to acquire Meridian Bioscience in an all-cash transaction valued at approximately $1.53 billion ( $34.00 per share). The deal will take Meridian private and is intended to accelerate SD Biosensor's entry into the U.S. in-vitro diagnostics market while leveraging Meridian's U.S. distribution network and product portfolio.
- Buyers
- SD Biosensor, Inc., SJL Partners LLC
- Targets
- Meridian Bioscience, Inc.
- Sellers
- Meridian Bioscience shareholders
- Industry
- Medical Devices
- Location
- Ohio, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pace Life Sciences Acquires Meridian BioGroup
August 18, 2022
Healthcare Services
Pace Life Sciences, a CDMO and subsidiary of Pace Science and Technology Company, has acquired Meridian BioGroup, a validation, regulatory, and compliance consulting provider based in Frederick, Maryland. The deal expands Pace's regulatory, quality and validation capabilities to better support biotechnology and pharmaceutical clients across development and commercialization.
-
Bioscript Group (backed by Sovereign Capital Partners) Acquires Meridian HealthComms
April 19, 2022
Healthcare Services
Bioscript Group, a Sovereign Capital Partners-backed healthcare communications platform headquartered in Macclesfield, has acquired Meridian HealthComms. The deal is Bioscript's third acquisition since Sovereign backed the management team in March 2021 and expands the group's geographic footprint and service capabilities in medical communications, regulatory writing and market access.
-
Merck to Acquire Imago BioSciences, Inc.
November 21, 2022
Pharmaceuticals
Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
-
Sherlock Biosciences Acquires Sense Biodetection
February 1, 2023
Biotechnology
Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.
-
Merck & Co. Acquires Cidara Therapeutics
January 8, 2026
Biotechnology
Merck & Co., through subsidiary Merck Sharp & Dohme LLC, completed a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per share, making Cidara a wholly owned subsidiary. The acquisition adds Cidara's long-acting antiviral candidate CD388 to Merck's respiratory portfolio and is being accounted for as an asset acquisition.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.